Landete Pedro, Fernández-García Carlos Ernesto, Aldave-Orzaiz Beatriz, Hernández-Olivo Marta, Acosta-Gutiérrez Carmen M, Zamora-García Enrique, Ancochea Julio, González-Rodríguez Águeda, García-Monzón Carmelo
Servicio de Neumología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain.
Departamento de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Front Med (Lausanne). 2022 Feb 23;9:808417. doi: 10.3389/fmed.2022.808417. eCollection 2022.
Given that obstructive sleep apnea (OSA) is commonly associated with metabolic disorders, in this prospective study, we sought to determine the prevalence and risk factors for hepatosteatosis, non-alcoholic steatohepatitis (NASH), and advanced liver fibrosis in patients with clinical and polygraphic criteria of OSA ( = 153) and in subjects with normal lung function parameters (NLP, = 43).
Hepatosteatosis, NASH, and advanced liver fibrosis were determined by blood-based non-invasive tools, such as the fatty liver index and the hepatic steatosis index, a serum lipidomic (OWLiver™) test, and three distinct fibrosis algorithms, respectively. Logistic regression models adjusted by potential confounders were performed to evaluate risk factors.
Insulin resistance and dyslipidemia were more frequent in patients with OSA than in subjects with NLP. The prevalence of hepatosteatosis was significantly higher in patients with OSA than in subjects with NLP. NASH was also found more frequently in patients with OSA than in subjects with NLP. In contrast, advanced liver fibrosis was rarely detected in the entire study population, and no significant differences were observed between patients with OSA and subjects with NLP. Besides male gender, increased body mass index (BMI), and presence of type 2 diabetes, percentage of sleep time with oxygen saturation <90% (Tc90%) was the only polygraphic variable significantly associated with NASH in patients with OSA.
This study shows that hepatosteatosis and NASH are highly prevalent in patients with OSA and indicates that those with a Tc90% higher than 10% are at increased risk for NASH.
鉴于阻塞性睡眠呼吸暂停(OSA)通常与代谢紊乱相关,在这项前瞻性研究中,我们试图确定符合OSA临床和多导睡眠图标准的患者(n = 153)以及肺功能参数正常的受试者(NLP,n = 43)中肝脂肪变性、非酒精性脂肪性肝炎(NASH)和晚期肝纤维化的患病率及危险因素。
分别通过基于血液的非侵入性工具,如脂肪肝指数和肝脂肪变性指数、血清脂质组学(OWLiver™)检测以及三种不同的纤维化算法来确定肝脂肪变性、NASH和晚期肝纤维化。采用经潜在混杂因素调整的逻辑回归模型来评估危险因素。
OSA患者的胰岛素抵抗和血脂异常比NLP受试者更常见。OSA患者的肝脂肪变性患病率显著高于NLP受试者。OSA患者中NASH的发现频率也高于NLP受试者。相比之下,在整个研究人群中很少检测到晚期肝纤维化,OSA患者和NLP受试者之间未观察到显著差异。除了男性、体重指数(BMI)增加和2型糖尿病的存在外,氧饱和度<90%的睡眠时间百分比(Tc90%)是OSA患者中与NASH显著相关的唯一多导睡眠图变量。
本研究表明,肝脂肪变性和NASH在OSA患者中高度普遍,并表明Tc90%高于10%的患者患NASH的风险增加。